Form 8-K Celldex Therapeutics, For: Mar 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St on track for subdued September start as high yields, oil prices dent sentiment
- Oil up more than 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
Roth Slashes PT on Celldex (CLDX) to $7; Rintega Phase 3 Update 'Disappointing' Given Prior Consistency
March 7, 2016 11:31 AM ESTRoth Capital cuts its price target on Celldex Therapeutics (Nasdaq: CLDX) from $39 down to $7 and removes the stock from its Focus List after Celldex announced that the ACT IV Phase III for Rintega in front-line glioblastoma was halted for futility.
Analyst Joseph Pantginis commented, The... More
Leerink Partners Downgrades Celldex Therapeutics (CLDX) to Market Perform
March 7, 2016 11:13 AM ESTLeerink Partners downgraded Celldex Therapeutics (NASDAQ: CLDX) from Outperform to Market Perform with a price target of $4.00 after the DSMB for the pivotal ACT IV study of Rintega/rindopepimut (EGFRvIII-directed cancer vaccine) in newly diagnosed glioblastoma recommended stopping the study for futility at the 2nd planned... More
